We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Immunoassay Module Launched Doubling Immunochemistry Tests

By LabMedica International staff writers
Posted on 03 Aug 2016
Print article
Image: The cobas e 801 immunoassay module (Photo courtesy of Roche Diagnostics).
Image: The cobas e 801 immunoassay module (Photo courtesy of Roche Diagnostics).
As diagnostic laboratories evolve to meet growing workloads in an increasingly challenging environment, a new immunoassay module offers high value through its flexibility, which allows for the efficient use of existing resources such as space, infrastructure and personnel.

The module is designed for maximum consolidation at a high throughput, continuous operation and, at the same time, it reduces the amount of waste generated, for more environmentally friendly testing and is now available for countries accepting the Conformité Européene (CE) Mark.

The cobas e 801 module (Roche Diagnostics, Basel, Switzerland) almost doubles the currently available immunochemistry testing capacity on the same footprint. The system only requires a low sample volume, offers an extensive assay menu and delivers fast, reliable and consistent patient results across systems. This benefits patients and healthcare professionals by providing the accurate and timely results needed to make the correct treatment decisions.

The cobas e 801 module is the newest member of the cobas 8000 modular analyzer series. It offers more than 100 immunoassays, across a wide range of disease areas. Up to four cobas e 801 modules can be configured in series, delivering up to 1,200 tests per hour across up to 192 reagent positions. The possible turn-around times for routine and emergency samples are the lowest available on the central laboratory market, with 18 minutes for routine and nine minutes for emergency tests, for instance with cardiac markers.

The small sample volumes required for testing are especially beneficial for critical patients, such as neonates and oncology patients. The cobas e 801 module uses the well-established Elecsys technology. The cobas e 801 allows for continuous loading of reagents and consumables and has a high uptime while requiring less hands-on time. Roland Diggelmann, MBA, the CEO Roche Diagnostics, said, “Today, laboratories need to deliver more diagnostic tests than ever before, while in many cases their resources are constrained. The cobas e 801 module is an important part of Roche’s connected laboratory solutions that allows laboratories to test efficiently and to sustainably grow their testing capacity.”

Related Links:
Roche Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more